SCHEMBL378288

SCHEMBL378288

OCCc1ccc(-c2cc(O)cc(O)c2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.60
ABL1 P00519 4/20 0.56
ABCB1 P08183 4/20 0.56
BCR P11274 4/20 0.56
LTA4H P09960 1/20 0.50
KDM4E B2RXH2 1/20 0.48
ALDH1A1 P00352 1/20 0.48
ALOX5 P09917 1/20 0.48
GAA P10253 1/20 0.48
MAPT P10636 1/20 0.48
BACE1 P56817 1/20 0.48
NPC1 O15118 1/20 0.45
TP53 P04637 1/20 0.45
MAPK1 P28482 1/20 0.45
CASP3 P42574 1/20 0.45
RAB9A P51151 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
SENP8 Q96LD8 1/20 0.45
SENP7 Q9BQF6 1/20 0.45
SENP6 Q9GZR1 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10458523 0.84 CA2 (0.85) CA2LTA4HKDM4EALDH1A1ALOX5
SCHEMBL17072102 0.83 ABL1 (0.46) CA2ABL1ABCB1BCRLTA4H
SCHEMBL2044945 0.83 CA2 (0.65) CA2KDM4EALDH1A1ALOX5GAA
SCHEMBL2090372 0.78 ABL1 (0.88) CA2ABL1ABCB1BCRALDH1A1
SCHEMBL17547068 0.78 ESR1 (0.65) CA2ABL1ABCB1BCRLTA4H
SCHEMBL19116594 0.78 CA2 (0.54) CA2KDM4EALDH1A1ALOX5GAA
SCHEMBL7700731 0.77 CHKA (0.50) CA2KDM4EALDH1A1ALOX5GAA
SCHEMBL15823399 0.76 PTGS2 (0.66) KDM4EALDH1A1MAPTTP53ESR1
Tyrosol SCHEMBL43838 0.76 CA2 (1.00) CA2LTA4HKDM4EALDH1A1ALOX5
SCHEMBL2987619 0.76 ACHE (0.60) CA2LTA4HKDM4EALDH1A1ALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250090554-A1 A METHOD OF TREATING DEPRESSION BY IMMUNE MODULATION MYND LIFE SCIENCES INC (CA) 2025-03-20 US disclosed
US-8313669-B2 Liquid-crystal display MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2012-11-20 US disclosed
US-8313669-B2 Liquid-crystal display MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2012-11-20 US disclosed
US-8313669-B2 Liquid-crystal display MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2012-11-20 US disclosed
EP-2181174-B1 LIQUID CRYSTAL DISPLAY MERCK PATENT GMBH (DE) 2012-01-25 EP disclosed
EP-2181174-B1 LIQUID CRYSTAL DISPLAY MERCK PATENT GMBH (DE) 2012-01-25 EP disclosed
US-20110101269-A1 LIQUID-CRYSTAL DISPLAY MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-05-05 US disclosed
US-20110101269-A1 LIQUID-CRYSTAL DISPLAY MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-05-05 US disclosed
US-20110101269-A1 LIQUID-CRYSTAL DISPLAY MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-05-05 US disclosed
EP-2181174-A1 LIQUID CRYSTAL DISPLAY Merck Patent GmbH (DE) 2010-05-05 EP disclosed
WO-2009030322-A1 LIQUID CRYSTAL DISPLAY MERCK PATENT GMBH (DE) 2009-03-12 WO disclosed
WO-2009030322-A1 LIQUID CRYSTAL DISPLAY MERCK PATENT GMBH (DE) 2009-03-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110101269-A1 LIQUID-CRYSTAL DISPLAY KLK3, LPXN, PSAP CA2 2331/4885ABL1 670/4885ABCB1 4224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.